TORONTO, ONTARIO--(Marketwire - March 14, 2012) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced the appointment of Mr. Tom Rossi to the role of President and Chief Operating Officer. Mr. Rossi originally joined the company in August 2011 as President and has led the Company's corporate and business development efforts.

Prior to joining Trimel, Mr. Rossi was engaged both domestically and internationally by Novartis Pharmaceuticals as the Chief Executive Officer for operating businesses in Belgium and most recently in Canada. Mr. Rossi holds a BSc from McGill University and an MBA from Concordia University in Montreal. He has more than 24 years of industry experience working for companies such as Johnson & Johnson, Boehringer Mannheim, Merck & Co. and Novartis. Mr. Rossi has management experience gained at all corporate levels within the healthcare industry and product/market experience in diagnostics, vaccines and traditional pharmaceutical products.

As Chief Operating Officer, Mr. Rossi becomes responsible for all of the daily operations of Trimel's business with immediate effect and will continue to report to the CEO.

Chairman of the Board and Chief Executive Officer Bruce Brydon commented: "Since Tom joined the Company, he has quickly integrated himself into the fabric of our operations and has gained a formative knowledge of our business as a public issuer in the Specialty Pharmaceuticals segment".

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing at more than 30 sites across America. CompleoTRT™ is for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit [ www.trimelpharmaceuticals.com ].

Publication Contributing Sources

• Market Wire